Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Vera Therapeutics (Nasdaq: VERA) announced that on November 4, 2025 its Compensation Committee granted inducement awards to six new employees under the 2024 Inducement Plan.
The awards include non-qualified stock options to purchase 79,050 shares and restricted stock units covering 39,915 shares. Each option has an exercise price of $24.35, equal to Vera Therapeutics’ closing price on November 4, 2025.
Vesting: options vest over four years with 25% on the first anniversary then monthly over 36 months; RSUs vest over four years with 25% vesting on each anniversary beginning November 20, 2025. Awards are subject to the Inducement Plan and applicable award agreements and were approved as inducements under Nasdaq Listing Rule 5635(c)(4).
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, VERA declined 4.08%, reflecting a moderate negative market reaction. This price movement removed approximately $66M from the company's valuation, bringing the market cap to $1.55B at that time.
Data tracked by StockTitan Argus on the day of publication.
BRISBANE, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on November 4, 2025, the Compensation Committee of the Board of Directors of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 79,050 shares of Class A common stock and restricted stock units (RSUs) underlying 39,915 shares of Class A common stock to six (6) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan). The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Each stock option granted on November 4, 2025 has an exercise price per share equal to
About Vera Therapeutics
Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera Therapeutics’ mission is to advance treatments that target the source of immunological diseases in order to change the standard of care for patients. Vera Therapeutics’ lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including immunoglobulin A nephropathy (IgAN) and lupus nephritis. Beyond IgAN, Vera Therapeutics is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove clinically meaningful. In addition, Vera Therapeutics holds an exclusive license agreement with Stanford University for a novel, next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B-cell-mediated diseases. Vera Therapeutics is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus, which can have devastating consequences in kidney transplant recipients. Vera Therapeutics retains all global developmental and commercial rights to atacicept, VT-109 and MAU868. For more information, please visit www.veratx.com.
For more information, please contact:
Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com
Media Contact:
Debra Charlesworth
Vera Therapeutics
415-854-8051
corporatecommunications@veratx.com
FAQ
What inducement awards did Vera Therapeutics (VERA) grant on November 4, 2025?
What is the exercise price for the VERA stock options granted November 4, 2025?
How do the VERA option and RSU vesting schedules work for the November 2025 grants?
How many employees received inducement awards from Vera Therapeutics on November 4, 2025?
Under what Nasdaq rule were the VERA inducement awards approved?
